No Detail Found!

Management of Clostridium difficile in a developing nation

Author(s)
Azadeh Nasrollah Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Shiva Hashemi Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Parvin Talebloo Department of Clinical Pharmacy, Prescribing Analysis and Auditing Centre, Boali Teaching Hospital, Tehran, Iran
Mehdi Rajabi Department of Clinical Pharmacy, Islamic Azad University Pharmaceutical Sciences Branch, Tehran, Iran
Syed Azhar Syed Sulaiman Department of Clinical Pharmacy, Universiti Sains Malaysia, Penang, Malaysia
Usman Abubakar Department of Clinical Pharmacy, Universiti Sains Malaysia, Penang, Malaysia
Abstract
Introduction: Clostridium difficile is the most important definable cause of healthcare acquired diarrhea. Recommended treatments for Clostridium difficile infection (CDI) are metronidazole, oral vancomycin and fidaxomicin (a new narrow spectrum macrocyclic antibiotic). Aim: The aim of this investigation was to review the treatment of CDI in Iran. Method: 1600 medical records and prescriptions were scrutinized for patients complaining of diarrhea, colitis and gastroenteritis. The therapeutic route was investigated in each individual case bearing in mind the medical and medication history as well as other com-orbidities. Results: The selection of antibiotic by many medical practitioners for the treatment of diarrhea, colitis and gastroenteritis were inappropriate and random. In most cases the chosen antibiotic, can itself be associated with initiation or worsening of CDI. Conclusion: The needs for antimicrobial stewardship program to preserve the effectiveness of current available therapies are strongly recommended. This program must focus on the overall reduction of inappropriate antibiotic prescribing and ultimately on enforcing the adherence to the reputable antibacterial guidelines.
Publication Details
Page(s) 172-177
Published Journal: Archives of Pharmacy Practice, Volume: 7, Issue: 4, Year: 2016

Request the full text from PASTIC

Keywords
Colitis, Outpatients, Clostridium difficile, Inpatient, fidaxomicin
References
Navaneethan U,Venkatesh PG,Shen B .2010 .Clostridium difficile infection and inflammatory bowel disease: Understanding the evolving relationship. World J Gastroenterol, 16 : 4892-904.
Sears P,Crook DW,Louie TJ,Miller MA,Weiss K. .2012 .Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis, 55(Suppl 2) : S116-20.
Nerandzic M,Mullane K,Miller M,Babakhani F,Donskey C .2012 .Reduced acquisition and over growth of vancomycin‑resistant enterococci and Candida species in patients treated with Fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis, 55 : S1216.
Louie TJ,Cannon K,Byrne B,Emery J,Ward L,Eyben M .2012 .Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis, 55(Suppl 2) : S132-42.
Daniels T,So TY .2011 .Fidaxomicin for the Treatment of Clostridium difficile infection in the pediatric population - Not quite so soon yet. Gastroenterol Res, 4 : 93-6.
Louie TJ,Miller MA,Mullane KM,Weiss K,Lentnek A,Golan Y .2011 .Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med, 364 : 4223-1.
Wilkins TD,Lyerly DM .2003 .Clostridium difficile testing: After 20 years, still challenging. J Clin Microbiol, 41 : 5314.
Gerding DN,Johnson S,Peterson LR,Mulligan ME,Silva J .1995 .Clostridium difficile‑associated diarrhea and colitis. Infect Control Hosp Epidemiol, 16 : 459-77.
Walley T,Milson D. .1990 .Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J, 66 : 582.
Ananthakrishnan AN,Issa M,Binion DG .2010 .Clostridium difficile and inflammatory bowel disease. Med Clin North Am, 94 : 135-53.
Hashemi S,Nasrollah A,Rajabi M. .2013 .Irrational antibiotic prescribing: A local issue or global concern?. EXCLI J, 12 : 384-95.
Ambrose N. .1989 .The effects of single doses of antibiotics on fecal flora with a reference to their mode of excretion. J Drug Dev, : 233-41.
Bartlett JG. .2002 .Clinical practice. Antibiotic‑associated diarrhea. N Engl J Med, 346 : 334-9.
Bignardi GE .1998 .Risk factors for Clostridium difficile infection. J Hosp Infect, 40 : 1-15.
Gaynes R,Rimland D,Killum E,Lowery HK,Johnson TM,Killgore G .2004 .Outbreak of Clostridium difficile infection in a long‑term care facility: Association with gatifloxacin use. Clin Infect Dis, 38 : 640-5.
Loo VG,Poirier L,Miller MA,Oughton M,Libman MD,Michaud S .2005 .A predominantly clonal multii‑nstitutional outbreak of Clostridium difficile‑associated diarrhea with high morbidity and mortality. N Engl J Med, 353 : 2442-9.
Pépin J,Saheb N,Coulombe MA,Alary ME,Corriveau MP,Authier S .2005 .Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficilea‑ssociated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis, 41 : 1254-60.
.2006 .S u n e n s h i n e R H , M c D o n a l d L C . C l o s t r i d i u m difficile‑associated disease: New challenges from an established pathogen. Cleve Clin J Med, 73 : 187-97.
0

Citations

0

Downloads

9

Views